Search

Displaying results 4291 - 4300 of 7018 in total
  1. Drug

    Hexamethonium

    go.drugbank.com/drugs/DB08960
    Experimental

    used a research tool. … A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier.

  2. Drug

    DTX-101

    go.drugbank.com/drugs/DB17699
    Investigational

    DTX-101 is an investigational gene therapy consisting of an adeno-associated virus serotype Rh10 vector encoding the human Factor Ix gene. … It was previously investigated for the treatment of hemophilia B; however, the clinical development of DTX-101 was discontinued.[L46103]

  3. Drug

    Alvocidib

    go.drugbank.com/drugs/DB03496
    Investigational

    Alvocidib is a synthetic flavonoid based on an extract from an Indian plant for the potential treatment of cancer. … It works by inhibiting cyclin-dependent kinases, arresting cell division and causing apoptosis in non-small lung cancer cells.

  4. Drug

    Zebularine

    go.drugbank.com/drugs/DB03068
    Experimental

    A chemically stable, cytidine analog that displays anti-tumor properties. It acts as a transition state analog inhibitor of cytidine deaminase by binding to the active site as covalent hydrates.

  5. Drug

    Cirazoline

    go.drugbank.com/drugs/DB09202
    Experimental

    Cirazoline acts on a number of α adrenergic receptors. It is an agonist of α1A, partial agonist of α1B and α1D, and a nonselective antagonist of α2. … It is believed that this combination of properties could make cirazoline an effective vasoconstricting agent.

  6. Drug

    ENTR-601-44

    go.drugbank.com/drugs/DB17836
    Investigational

    ENTR-601-44 is an exon 44 skipping phosphorodiamidate morpholino oligonucleotide (PMO). Developed by Entrada Therapeutics, it was investigated for the treatment of Duchenne muscular dystrophy.[L46641]

  7. Drug

    PAS-004

    go.drugbank.com/drugs/DB18611
    Investigational

    PAS-004 is an allosteric MEK 1/2 inhibitor being developed by Pasithea Therapeutics. It is being investigated for the treatment of neurofibromatosis 1 and Noonan syndrome.

  8. Drug

    Pentetrazol

    go.drugbank.com/drugs/DB13415
    ApprovedWithdrawn

    Pentetrazol, also known as pentylenetetrazole, is a gamma-aminobutyric acid type A (GABA<sub>A</sub>) receptor antagonist that was approved by the FDA until 1982.[A254437]

  9. Drug

    Cocarboxylase

    go.drugbank.com/drugs/DB01987
    ApprovedInvestigational

    It is a required intermediate in the pyruvate dehydrogenase complex and the ketoglutarate dehydrogenase complex.

  10. Drug

    Tenamfetamine

    go.drugbank.com/drugs/DB01509
    IllicitInvestigational

    An amphetamine derivative that inhibits uptake of catecholamine neurotransmitters. It is a hallucinogen. … It is less toxic than its methylated derivative but in sufficient doses may still destroy serotonergic neurons and has been used for that purpose experimentally. [PubChem]